Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1311-1321

  Dixit, Saurabh ^a   Singh, Shree R ^a   Yilma, Abebayehu N ^a,b   Agee, Ronald D ^a,c   Taha, Murtada ^a,d   Dennis, Vida A ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d ALBANY STATE UNIVERSITY   (United States)

Author keywords

Antibody; Bacteria; Chlamydia trachomatis; Cytokines; PLA PEG nanoparticles

Indexed keywords

ANTIBODIES; BACTERIA; BIOCOMPATIBILITY; BIOLOGICAL MEMBRANES; ENCAPSULATION; IMMUNE SYSTEM; MACROPHAGES; MAMMALS; NANOPARTICLES; PEPTIDES; POLYETHYLENE OXIDES; T-CELLS; VACCINES;

ADAPTIVE IMMUNE RESPONSE; BIODEGRADABLE COPOLYMERS; CHLAMYDIA TRACHOMATIS; CYTOKINES; ENCAPSULATION EFFICIENCY; MAJOR OUTER MEMBRANE PROTEINS; NANOPARTICLE FORMULATION; PLA-PEG;

POLYETHYLENE GLYCOLS;

B7 ANTIGEN; COPOLYMER; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 17; INTERLEUKIN 2; MACROGOL; NANOCARRIER; OUTER MEMBRANE PROTEIN; POLYLACTIC ACID; RECOMBINANT MOMP 278; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; BACTERIAL VACCINE; DRUG CARRIER; LACTIC ACID DERIVATIVE; MACROGOL DERIVATIVE; NANOPARTICLE; POLY(LACTIC ACID-ETHYLENE GLYCOL);

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL INFECTION; CHLAMYDIA TRACHOMATIS; CYTOTOXICITY; DOWN REGULATION; FEMALE; IMMUNIZATION; IN VITRO STUDY; MACROPHAGE; MOUSE; NANOENCAPSULATION; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TH17 CELL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHLAMYDIA INFECTIONS; IMMUNOLOGY;

CHLAMYDIA; CHLAMYDIA TRACHOMATIS; MUS;

ADAPTIVE IMMUNITY; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DRUG CARRIERS; FEMALE; LACTATES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84905254847     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.02.009     Document Type: Article

References (50)

1. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
2. Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009, 61:140-157.
3. Kalkanidis M., Pietersz G.A., Xiang S.D., Mottram P.L., Crimeen-Irwin B., Ardipradja K., Plebanski M. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 2006, 40:20-29.
4. Irache J.M., Esparza I., Gamazo C., Agüeros M., Espuelas S. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet Parasitol 2011, 180:47-71.
5. Ishihara T., Takahashi M., Higaki M., Mizushima Y., Mizushima T. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int J Pharm 2010, 385:170-175.
6. De Souza Rebouças J., Esparza I., Ferrer M., Sanz M.L., Irache J.M., Gamazo C. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol 2012, 2012:474605.
7. Essa S., Louhichi F., Raymond M., Hildgen P. Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles. J Microencapsul 2013, 30:205-217.
8. Jain A.K., Goyal A.K., Gupta P.N., Khatri K., Mishra N., Mehta A., Mangal S., Vyas S.P. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J Control Release 2009, 136:161-169.
9. Sheringham J., Mann S., Simms I., Stafford M., Hart G.J., Raine R. It matters what you measure: a systematic literature review examining whether young people in poorer socioeconomic circumstances are more at risk of chlamydia. Sex Transm Infect 2013, 89:175-180.
10. Hafner L., Beagley K., Timms P. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol 2008, 1:116-130.
11. Singh S.R., Hulett K., Pillai S.R., Dennis V.A., Oh M.K., Scissum-Gunn K. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 2006, 24:1213-1224.
12. Champion C.I., Kickhoefer V.A., Liu G., Moniz R.J., Freed A.S., Bergmann L.L., Vaccari D., Raval-Fernandes S., Chan A.M., Rome L.H., Kelly K.A. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 2009, 4:e5409.
13. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
14. Sandhya M., Srinivas P., Sadanandam M. Nanoparticulate systems and other novel approaches in the diagnosis, prevention and treatment of HIV/AIDS. Int J Pharm Sci 2010, 2:738-749.
15. Taha M.A., Singh S.R., Hulett K., Pillai S.R., Agee R., Dennis V.A. A peptide containing T-cell epitopes of Chlamydia trachomatis recombinant MOMP induces systemic and mucosal antibody responses in mice. WJV 2011, 1:138-147.
16. Taha M.A., Singh S.R., Dennis V.A. Biodegradable PLGA 85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology 2012, 23:325101.
17. Fairley S.J., Singh S.R., Yilma A.N., Waffo A.B., Subbarayan P., Dixit S., Taha M.A., Cambridge C.D., Dennis V.A. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper-1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine 2013, 8:2085-2099.
18. Cambridge C.D., Singh S.R., Waffo A.B., Fairley S.J., Dennis V.A. Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomedicine 2013, 8:1759-1771.
19. Yilma A.N., Singh S.R., Dixit S., Dennis V.A. Anti-inflammatory effects of silver-polyvinyl pyrrolidone (Ag-PVP) nanoparticles in mouse macrophages infected with live Chlamydia trachomatis. Int J Nanomedicine 2013, 8:2421-2432.
20. Gautam A., Dixit S., Embers M., Gautam R., Philipp M.T., Singh S.R., Morici L., Dennis V.A. Different patterns of expression and of IL-10 modulation of inflammatory mediators from macrophages of Lyme disease-resistant and -susceptible mice. PLoS One 2012, 7:e43860.
21. Yilma A.N., Singh S.R., Morici L., Dennis V.A. Flavonoid naringenin: a potential immunomodulator for Chlamydia trachomatis inflammation. Mediators Inflamm 2013, 2013:102457.
22. Yilma A.N., Singh S.R., Fairley S.J., Taha M.A., Dennis V.A. The anti-inflammatory cytokine, interleukin-10, inhibits inflammatory mediators in human epithelial cells and mouse macrophages exposed to live and UV-inactivated Chlamydia trachomatis. Mediators Inflamm 2012, 2012:520174.
23. Ahmed F., Discher D.E. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J Control Release 2004, 96:37-53.
24. Waeckerle-Men Y., Gander B., Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005, 109:35-46.
25. Wu F., Jin T. Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech 2008, 9:1218-1229.
26. Gutierro I., Hernández R.M., Igartua M., Gascón A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77.
27. Xiao R.Z., Zeng Z.W., Zhou G.L., Wang J.J., Li F.Z., Wang A.M. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine 2010, 5:1057-1065.
28. Wang B., Jiang W., Yan H., Zhang X., Yang L., Deng L., Singh G.K., Pan J. Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium. Int J Nanomedicine 2011, 6:1443-1451.
29. Makoto M., Ken H., Tsutomu O. PEG-PLA nanoparticles prepared by emulsion solvent diffusion using oil-soluble and water-soluble PEG-PLA. Mater Lett 2010, 64:969-971.
30. Vila A., Sánchez A., Tobío M., Calvo P., Alonso M.J. Design of biodegradable particles for protein delivery. J Control Release 2002, 78:15-24.
31. Vonarbourg A., Passirani C., Saulnier P., Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373.
32. Alonso M.J., Gupta R.K., Min C., Siber G.R., Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12:299-306.
33. Mainardes R.M., Khalil N.M., Gremião M.P. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int J Pharm 2010, 395:266-271.
34. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
35. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., Tchilian E.Z. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
36. Morré S.A., Karimi O., Ouburg S. Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics. FEMS Immunol Med Microbiol 2009, 55:140-153.
37. Hu V.H., Holland M.J., Burton M.J. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis 2013, 7:e2020.
38. Karunakaran K.P., Yu H., Foster L.J., Brunham R.C. Development of a Chlamydia trachomatis T-cell vaccine. Hum Vaccin 2010, 6:676-680.
39. Zhang Y., Wang H., Ren J., Tang X., Jing Y., Xing D., Zhao G., Yao Z., Yang X., Bai H. IL-17A synergizes with IFN-γ to upregulate iNOS and NO production and inhibit chlamydial growth. PLoS One 2012, 7:e39214.
40. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
41. Olive A.J., Gondek D.C., Starnbach M.N. CXCR3 and CCR5 are both required for T-cell-mediated protection against Chlamydia trachomatis infection in the murine genital mucosa. Mucosal Immunol 2011, 4:208-216.
42. Hickey D.K., Bao S., Ikeda L.T., Carey A.J., Beagley K.W. Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. Curr Mol Med 2005, 5:599-605.
43. Lu H., Xing Z., Brunham R.C. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol 2002, 169:6324-6331.
44. Hansen J., Jensen K.T., Follmann F., Agger E.M., Theisen M., Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis 2008, 198:758-767.
45. Morrison S.G., Morrison R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005, 175:7536-7542.
46. Igietseme J.U., Eko F.O., He Q., Black C.M. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004, 3:23-34.
47. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 1997, 15:575-582.
48. Peterson E.M., Cheng X., Motin V.L., de la Maza L.M. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 1997, 65:2693-2699.
49. Massari P., Toussi D.N., Tifrea D.F., de la Maza L.M. Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect Immun 2013, 81:303-310.
50. Chen L., Cheng W., Shivshankar P., Lei L., Zhang X., Wu Y., Yeh I.T., Zhong G. Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice. Infect Immun 2009, 77:3080-3089.